The tumor microenvironment (TME) plays a vital role in the development, progression, and metastasis of pancreatic cancer (PC). The composition of the TME and its potential prognostic value remains to be fully understood, especially in adenosquamous carcinoma of pancreas (ASCP) patients. Immunohistochemistry was used to explore the clinical significance of CD3, CD4, CD8, FoxP3, and PD-L1 expression within the TME and to identify correlations with the prognosis of PC in a series of 29 patients with ASCP and 54 patients with pancreatic ductal adenocarcinoma (PDAC). Data from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) were accessed to obtain the scRNA-seq data and transcriptome profiles. Seurat was used to process the ...
The high progression rate of Pancreatic Ductal Adenocarcinoma (PDAC) depends on intrinsic genetic an...
International audienceAbstract Background The prognosis of patients with pancreatic cancer remains p...
Immune checkpoint therapy (ICT) has shown promising potential in the treatment of multiple solid tum...
Abstract Background Both activated tumor-infiltrating lymphocytes (TILs) and immune-suppressive cell...
Pancreatic ductal adenocarcinoma (PDAC) is an extremely malignant tumor. The immune profile of PDAC ...
Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor characterized by rapid progression, ear...
Pancreatic ductal adenocarcinoma (PDAC) is considered to be a poorly immunogenic cancer type that co...
We examined the prognostic value of programmed cell death-1 (PD-1) and its ligand (PD-L1) together w...
BackgroundWe investigated the correlation between pancreatic ductal adenocarcinoma patient prognosis...
The expression of PD-L1 could be a novel biomarker which predicts that patients are more likely to r...
In patients with pancreatic ductal adenocarcinoma (PDAC), the tumor microenvironment consists of cel...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest cancer worldwide...
Here we explore the role of the interplay between host immune response and epithelial-mesenchymal-tr...
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor and is insensitive to radiothera...
Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in pancreatic ductal adenoc...
The high progression rate of Pancreatic Ductal Adenocarcinoma (PDAC) depends on intrinsic genetic an...
International audienceAbstract Background The prognosis of patients with pancreatic cancer remains p...
Immune checkpoint therapy (ICT) has shown promising potential in the treatment of multiple solid tum...
Abstract Background Both activated tumor-infiltrating lymphocytes (TILs) and immune-suppressive cell...
Pancreatic ductal adenocarcinoma (PDAC) is an extremely malignant tumor. The immune profile of PDAC ...
Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor characterized by rapid progression, ear...
Pancreatic ductal adenocarcinoma (PDAC) is considered to be a poorly immunogenic cancer type that co...
We examined the prognostic value of programmed cell death-1 (PD-1) and its ligand (PD-L1) together w...
BackgroundWe investigated the correlation between pancreatic ductal adenocarcinoma patient prognosis...
The expression of PD-L1 could be a novel biomarker which predicts that patients are more likely to r...
In patients with pancreatic ductal adenocarcinoma (PDAC), the tumor microenvironment consists of cel...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest cancer worldwide...
Here we explore the role of the interplay between host immune response and epithelial-mesenchymal-tr...
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor and is insensitive to radiothera...
Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in pancreatic ductal adenoc...
The high progression rate of Pancreatic Ductal Adenocarcinoma (PDAC) depends on intrinsic genetic an...
International audienceAbstract Background The prognosis of patients with pancreatic cancer remains p...
Immune checkpoint therapy (ICT) has shown promising potential in the treatment of multiple solid tum...